Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mallory Morales is SVP Finance, CAO at Immuneering. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 5, 2026, each linked to the official Form 4.
SVP Finance, CAO
Disclosures on record
1
Companies involved
1
ImmuneeringIMRX
Feb 3, 2026140Kdisclosed Feb 5
DetailsOfficial recordMallory Morales reported 2 open-market purchases and 0 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Mallory Morales bought shares on the open market in 2024, and has not bought since 2024.
Mallory Morales reported 2 open-market purchases and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $4K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Mallory Morales bought shares on the open market in 2024, and has not bought since 2024.
In SEC filings since 2024: the latest open-market purchase is from 2024; no open-market sale is on record.
Immuneering (IMRX), from 2024 to 2024: 2 purchases and 0 sales.